Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial
Authors:
- 1 August 2015
- journal article
- research article
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 25 (6) , 482-493
Abstract
Objective: Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism. Less is known about the long-term effects of risperidone exposure in this population. We examined the tolerability, safety, and therapeutic benefit of risperidone exposure over a 1–2 year follow-up period. Methods: In a naturalistic study, 84 children and adolescents 5–17 years of age (from an original sample of 101) were assessed an average of 21.4 months after initial entry into a placebo-controlled 8 week trial of risperidone for children and adolescents with autism and severe irritability. They were assessed at baseline and at follow-up on safety and tolerability measures (blood, urinalysis, electrocardiogram [ECG], medical history, vital signs, neurological symptoms, other adverse events), developmental measures (adaptive behavior, intelligence quotient [IQ]), and standardized rating instruments. Treatment over the follow-up period, after completion of protocol participation, was uncontrolled. Statistical analyses assessed outcome over time with or without prolonged risperidone therapy. Results: Two-thirds of the 84 subjects continued to receive risperidone (mean 2.47 mg/day, S.D. 1.29 mg). At follow-up, risperidone was associated with more enuresis, more excessive appetite, and more weight gain, but not more adverse neurological effects. No clinically significant events were noted on blood counts, chemistries, urinalysis, ECG, or interim medical history. Regardless of drug condition at follow-up, there was considerable improvement in maladaptive behavior compared with baseline, including core symptoms associated with autism. Height and weight gains were elevated with risperidone. Social skills on Vineland Adaptive Behavior Scale (VABS) improved with risperidone. Parent-rated Aberrant Behavior Checklist (ABC) Irritability subscale scores were reduced in those taking risperidone at follow-up. Several other measures of maladaptive behavior (some related to socialization) also showed improved functioning in association with risperidone on the ABC or on the Modified Real Life Rating Scale. Conclusions: Increased appetite, weight gain, and enuresis are risks associated with long-term risperidone. Our data suggest that these risks were balanced by longer-term behavioral and social benefits for many children over 1.8 years of ongoing treatment.Keywords
This publication has 38 references indexed in Scilit:
- Safety and Tolerability of Aripiprazole for Irritability in Pediatric Patients With Autistic DisorderThe Journal of Clinical Psychiatry, 2011
- Aripiprazole in the Treatment of Irritability in Pediatric Patients (Aged 6–17 Years) with Autistic Disorder: Results from a 52-Week, Open-Label StudyJournal of Child and Adolescent Psychopharmacology, 2011
- Risperidone Use in Autism Spectrum Disorders: A Retrospective Review of a Clinic-Referred Patient PopulationJournal of Child Neurology, 2010
- Long-Term Safety and Adverse Events of Risperidone in Children, Adolescents, and Adults With Pervasive Developmental DisordersJournal of Mental Health Research in Intellectual Disabilities, 2010
- Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and AdolescentsJAMA, 2009
- Change in Autism Symptoms and Maladaptive Behaviors in Adolescents and Adults with an Autism Spectrum DisorderJournal of Autism and Developmental Disorders, 2006
- Medication Patterns in Patients with Autism: Temporal, Regional, and Demographic InfluencesJournal of Child and Adolescent Psychopharmacology, 2005
- Weight and Leptin Changes Among Risperidone-Treated Youths With Autism: 6-Month Prospective DataAmerican Journal of Psychiatry, 2004
- A power primer.Psychological Bulletin, 1992
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970